|
|
- たかとし さんきち
- 7 years ago
- Views:
Transcription
1
2
3
4
5
6 3
7 O157:H7 O139 VRSA H5N1) Nipah SARS prairie dog Chikungunya 4
8 H H A B B H C D 5
9 6
10 I.U.WHOCDC 7
11 MMWR VERO 8
12 100%92.3% 86.3% 40 % 50%12.5% 2.5% 30.8%
13 1(1) 26(19) 2(2) 1(1) 30(23) 0 24(18) 4(3) 2(1) 30(22) 0 75(21) 5(4) 0 80(25) 0 16(14) 2(2) 2(2) 20(18) 1(1) 13(11) 3(3) 1(1) 18(16) ( ) Nalidixic Acid () H H H 10
14 11
15 , 12
16 A 13
17
18 15
19 16
20 17
21 ( 250mg/ 100mg/ 18
22 19
23 20
24 21
25 GabonCongo Leroy, EM et al, Nature 2005;438:575-6 EV) Vesicular Stomatitis Virus (VSV)EV EV Plos Pathog. 2007;3(1):e2. 22
26 Mr. U.G 1 23
27 Child: Secondary lesions 5/27/03, adjacent to primary inoculation site on left hand. Marshfield Clinic Monkeypox lesions at a finger bitten by a prairie dog Marshfield Clinic / 0/0 0/0 0/0 8/58/5 0/0 0/0 4/4 2/2 6/6 1/1 0/0 8/5 12/8 21/14 0/0 0/0 0/0 1/0 1/0 0/0 0/0 0/0 15/6 15/6 0/0 0/0 19/12 50/40 69/52 0/0 0/0 0/0 3/2 3/2 0/0 17/12 5/2 3/3 8/5 0/0 0/0 0/0 12/4 12/4 3/3 29/20 61/19 0/0 93/42 4/4 46/32 97/42 106/ /148 24
28 in vitro 25
29 26
30 27
31 28
32 29
33
34 Prevention important B A () 1
35 A8,000 * 2
36 A ProMED 4/
37
38 B
39 0 6
40 1970 7
41 * 8
42 9
43
表1_表4
HN- 95 HN- 93 HN- 90 HN- 87 HN- 85 HN- 82 HN- 80 HN- 77 HN- 75 HN- 72 HN- 70 HN- 67 HN- 65 HN- 60 HN- 55 HN- 50 HN- 45 HN- 40 HN- 35 HN- 30 HN- 25 HN- 20 HN- 15 HN- 10 H02-80H H02-80L H02-70T H02-60H H05-60F
More information(1) 2000 ( ) ( ) 1000 2000 1000 0 http://www.spacepark.city.koriyama.fukushima.jp/ http://www.miraikan.jst.go.jp/ http://www.nasda.go.jp/ 3000 1 1 http://www.city.nara.nara.jp/citizen/jyugsidu/jgy/jsj/
More informationMicrosoft Word - 表紙資料2-4
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
More information1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR
More information!!! 10 1 110 88 7 9 91 79 81 82 87 6 5 90 83 75 77 12 80 8 11 89 84 76 78 85 86 4 2 32 64 10 44 13 17 94 34 33 107 96 14 105 16 97 99 100 106 103 98 63 at 29, 66 at 58 12 16 17 25 56
More informationuntitled
18 12 10 40 H5N1 2005 11 WHO 2005 12 2006 6 (H5N1) 10 25 1,700 ( 1,300 2,500 ) 200 53 64 17 30% 3,785,000 291,200 3 14,100 4 30% 57,600 4,430 3 1,150 320 210 4 2% 0.56% () ) 1 10 2 3A (2B) 3B 4A5A 6A 4B
More information平成18年度 第1回 海域ワーキンググループ 議事録 [PDF]
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - adjacent area - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 -
More information2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
More information001-007 扉・口絵・目次
1 6 6 7 1 a a a a 2 a a a 3 4 5 a 6 7 8 9 10 a 11 a a a 12 13 14 15 a 16 17 18 19 20 21 22 23 24 b b 25 b 26 27 aa 28 r r 29 a s d f 30 b b 31 32 33 1 34 35 36 37 38 6 39 6 40 41 42 43 44 45 7 47 48
More informationnsg02-13/ky045059301600033210
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
More informationSmall Animal Clinic C O N T E N T S NO.161 2 4 10 20 30 28 32 34 3 Small Animal Clinic No.161 4 5 6 Small Animal Clinic No.161 7 8 Small Animal Clinic No.161 9 Small Animal Clinic No.161 10 11 Small Animal
More informationSmall Animal Clinic NO.146 C O N T E N T S 2 4 11 16 19 24 28 30 34 3 3 Small Animal Clinic No.146 4 5 Small Animal Clinic No.146 6 7 Small Animal Clinic No.146 8 9 11 Small Animal Clinic No.146 12 13
More informationSmall Animal Clinic C O N T E N T S NO.154 2 4 10 18 28 31 32 34 3 3 Small Animal Clinic No.154 4 5 Small Animal Clinic No.154 6 7 Small Animal Clinic No.154 8 9 Small Animal Clinic No.154 10 11 Small
More information産衛誌57-4たより.indb
A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al
More information/‚“1/ŒxŒ{‚×›î’æ’¶
60 1 pp.3-8 2010 1. H1N1 1) 2) 3) 4) ERATO 2009 H1N1 21 H1N1 HA PB2 2009 3 Pandemic H1N1 2009 WHO 6 11 21 2009 11 2010 4 21 H1N1 H1N1 2009 4 15 CDC 108-8639 4-6-1 TEL: 03-5449-5281 FAX: 03-5449-5408 E-mail:
More information表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
More informationuntitled
6 ( ). 1.. 1. 2. 3. 4. 5. ( ) 6. 7. 8. . 1. 1) 1 (12 3 ) 2 2) 3) ( ) ( ) 4) 2 () 2 2 3 5) ( ) R-Book ATLAS () 8 12 7 18 14 16 10 21 14 23 16 18 16 18 12 25 4 14 21 1 4 2 3 4 4 1 2 7 5 1 2 5 7 9 1 1 5 5
More information200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
More information21世紀という時代
1 2 3 http://www.biosecuritysummit.com 4 5 6 7 8 - 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 Source: Newspaper in HongKong
More information131 1 74 1 4 19955% 5 19951% 74 51,4.34.9 7 1 8 4 88.5 48.3 49.4 49.8 49. 51.4 95 3 4 5 18. 18 17. 1. 1.8 1. 1 5 5. 14 4 1 4.1 4. 4. 4.1 1 3 8 4 1 3 4
515, 1 3 4 54,t 1 3 4 5 5 559 1 547 5 58 54 5 8 4 7.1 3 5. 5.9 5. 4.5 4 1 3 4 5 19 131 1 74 1 4 19955% 5 19951% 74 51,4.34.9 7 1 8 4 88.5 48.3 49.4 49.8 49. 51.4 95 3 4 5 18. 18 17. 1. 1.8 1. 1 5 5. 14
More information医薬品リスク管理計画書
2.5 mg 3.75 mg 5 mg 20mg RMP 2.5 mg 3.75 mg 5 mg 20mg 87339 28 6 1.1 4 8 10 5 8 10 5 TTP 9 梗 6 TIA 11 6 1.2 11 CABG 12 12 13 13 15 2.5mg 15 2. 16 3. 16 4. 19 19 19 18 RMP 28 6 3 5 1 27 8 25 26 3 24 87339
More information2011 2011 2011 100/m 0.003/ 0.0005 / 0.01/ 0.01 / 0.01/ 0.05 / 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005 0.001 0.001 0.001 0.005 0 0.0003 0.00005
More informationIF_SUPRECUR_N29
! @ # $ % ^ & * ( ) _ + )# ! a s d a s d f g h a s d @ a s d a s # a s d f g h j $ a s d f g h a s d % a s a a s a s a s d f g ^ a s a s a s & a s d f a s d f g h a s d f g a s d f g a s d a s d * s
More informationHIV1 IAS-USA 1 HIV 1 Amino Acid, Wild-Type Primary Mutation Amino Acid Substitution M I 54 Secondary Mutation Codon Mutation Selected In Vitro MUTATIONS IN THE PROTEASE GENE SELECTED BY PROTEASE INHIBITORS
More informationKRAS KRAS
KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS : KRAS in vitro KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS
More informationuntitled
25 486 1 17 3 1641 1 OA OA 1F 726 2F 662 F 1F 137 2F 1,321 3F 1,312 1,513 F 1,292 2F 1,155 1F 747 2F 747 40 2,770 3F 1,415 F F 1,494 18 508 EV EV ) ) 40kw 2~3 30m 777 16 1 16 16 7 16 800,000 790,000
More information437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
More information中国の憲法改正
2004 10 13 11 13 14 33 67 80 89 16 10 59 81 98 136 1982 12 1988 1993 1999 20 04 2004 1987 13 1988 1992 14 1993 1997 15 1999 2002 16 2004 60 2002 11 12 20 2003 10 28 2003 6 2003.10.28, 2003, p.16 2002 2002,
More informationuntitled
1 4 4 6 8 10 30 13 14 16 16 17 18 19 19 96 21 23 24 3 27 27 4 27 128 24 4 1 50 by ( 30 30 200 30 30 24 4 TOP 10 2012 8 22 3 1 7 1,000 100 30 26 3 140 21 60 98 88,000 96 3 5 29 300 21 21 11 21
More information: : 2001227 : 2
: : 2001227 : 2 mg/100gmg/100g mg/100g 3 10/102006 12/05 2/19, 2007 Zn 63 98 4 10% 5 Ramesh et al. 2004 6 Connoly et al. 2002 A IRT 7 8 2.11mg/100g143%56% 9 10 Alaria praelonga 11 2 12 13 14 15 16 1 1
More informationslide1.dvi
1. 2/ 121 a x = a t 3/ 121 a x = a t 4/ 121 a > 0 t a t = a t t {}}{ a a a t 5/ 121 a t+s = = t+s {}}{ a a a t s {}}{{}}{ a a a a = a t a s (a t ) s = s {}}{ a t a t = a ts 6/ 121 a > 0 t a 0 t t = 0 +
More information冊子_H26-03A
1 : [ ] by kouyou_room 2014-02-28 22:18 Comments(6) Commented by at 2014-03-01 10:27 x 2 Commented by at 2014-03-01 10:29 x Commented by at 2014-03-01 10:54 x Commented by at 2014-03-01 14:50 x Commented
More information13●53頁●6-7▲院内感染対策▲.ppt
No.610 1 No.121 2 No.128 Nosocomial infection, Hospital-acquired infection CDC nosocomial infection, hospital-acquired infection nosocomial nosokomeion hospital nosocomial infection nosocomial pneumonia
More informationuntitled
28 2016 26 28 4 1 28 2 4 (AMR) AMR RS A (SFTS) 鞭 29 12 20 1 4 6 7 7 7 8 13 21 22 23 24 25 26 28 30 32 33 34 35 36 40 66 70 78 84 87 87 89 92 92 93 105 105 105 106 107 108 109 110 111 111 112 112 112
More information14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
More information20●12頁●6-14▲放射線科▲.ppt
No.268 Katayama H. et al. Adverse reactions to ionic and nonionic contrast media-a report from the Japanese Committee of the Safety of Contrast Media. Radiology 1990;175:621-628. 12.66% 3.13% 0.22% 0.04%
More information2.2 (1967) (1997,2003) 2.2 ( ) 11
( ) 2.1 10 2.2 (1967) (1997,2003) 2.2 ( ) 11 12 ( ) 90150 (684) (887) (1099) (1361) (1605) (1707) (1854) 21(1946) 8 2.3 (1854) 13 (1997) (1854.12.23) (M8.4) (24 ) (M8.4) 70,000 3000 ( ) 7 2 3 3 (,1997)
More information[2] 2, 3 ( wrapfigure ) 2: 3: [3] [1] (1841). [2] (1886). [3] -.
80kg ( 1) C 60 1: ( Aρχiµήδηç) r(z) = 0.5 1 (e z 2) 2 ln 3 V = π r 2 (z)dz (1) 0 1: (kg/) 20mg 8 2.5mg 5t 4 1.3t 60kg 2 30kg 10kg 1 10kg 7kg 0 19 [1] [2] 2, 3 ( wrapfigure ) 2: 3: [3] [1] (1841). [2] (1886).
More information[ml] 180 160 140 120 100 80 60 40 20 0 Cumulative biogas production [ml/mg-input VS] 0 10 20 30 40 50 60 [] 1 0.8 0.6 0.4 0.2 0 dog food PLA foam 0 10 20 30 40 50 days RUN1-1 RUN1-2 RUN2-1 RUN2-2 RUN3-1
More informationUntitled art 3
2004 5 What s Inside 1 2 3 4 6 9 11 12 Visit our site at www.jccc-chi.org MAY 2004 NEWS CHICAGO 2 MAY 2004 NEWS CHICAGO 3 4 NEWS CHICAGO MAY 2004 MAY 2004 NEWS CHICAGO 5 6 NEWS CHICAGO MAY 2004 MAY 2004
More information日本損害保険協会
1995 1981 30cm 15cm 10cm 10cm 1998 38 24 78 0.5 1,0002,000 1984 2 1995 38 1995 1981 4 0.3 0.30.20.02 1 ex. 1960 km Body Wave Surface Wave Body Wave Primary wave Secondary
More information1 1881 14 1870 80 1870 1877 10 23 2 3 2 2 24 25 6 1884 17 1 1886 19 1 2 1879 12 1874 7 1879 1884 26 1884.11.2 1884.1.12. 1869 1878 1882 15 5 1884.5.1. 5.10. 27 Oh Lord Amen 1884.5.25. 2 28 2 2 2 2 29 3
More information:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
More informationuntitled
HCV 150 HCV 13 3 13 4 13 8 14 2 14 2 14 8 15 3 15 8 17 3 7 8 18 3 ----- i Q1 1 Q2 1 Q3 1 Q4 2 Q5 3 Q6 3 Q7 3 Q8 4 Q9 4 Q10 : 5 6 Q1 6 Q2 7 Q3 7 8 Q4 8 Q5HCV 8 Q6HCV 9 Q7HCV 9 Q8NAT 10 Q9 10 Q10 11 Q11
More information7th埼玉オープン.pm6
6 7 6 7 6-0 6 7 0 6-6 -0 7-0 -7 8 8 - - 9 0 0 - -8 9 0-6 -8 0 8- -7-6 6-0 -7 7 0 8-8 (by Mitsuhashi) 6 0- -8 6 7 8 6 7 9 0-8 8 9 0 7 6 8 9-8 6-8 0 7-7 - 8 9 0 - -0 7 6 6-7 - - - 9- -6 9 0 8-8 -0 - -7-7
More informationEstablishment and progress of Sendai virus engineering 2) Schnell, M. J., Mebatsion, T., Conzelmann, K.-K.: EMBO J., 13,4195-4203(1994) 3) Kato, A. et al.: Genes Cells, 1, 569-579 (1996) 4) Nagai,
More information日本目録規則1987年版改訂2版第2章図書改定案
2.0.1 2.0.2 2.0.3 2.0.4 2.0.5 2.0.6 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.2.1 2.2.2 2.2.3 2.2.4 2.4.1 2.4.2 2.4.3 2.4.4 2.5.1 2.5.2 2.5.3 2.5.4 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 ISSN 2.6.6 2.6.7 2.7.1 2.7.2 2.7.3
More informationBAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
More information14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=
DeCEMBER, 17 No.34 HIV 169-73 1-1-1-13TEL 3-5937-4413:3 19:3 FAX 3-5937-443E-mail info@janpplus.jp http://janpplus.jp/!9-9-9!... 1-3 POSITIVE HIV/AIDS UNAIDS!... 4-5 JaNP+HIV Cafe Bar an opportunity...
More information200812 06 Development 2
200812 06 Development 2 200812 06 Research and Clinical Center for Child Development 4 (CP) MR MR, MR, MR( PDD, PDD, ADHD, 200812 06 Research and Clinical Center for Child Development 5 LD LD ADHD ADHD
More informationVENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
More information/fiÁ1-1/‹Éfi¡ıæ„[’æ’¶
59 1 pp.53-58 2009 1. H5N1 3 H5N1 2007 1 2 2008 4 5 2003 H5N1 2005 50 1 429 262 2009 5 22 2 680-8553 4 101 TEL/FAX : 0857-31-5437 E-mail: toshiito@muses.tottori-u.ac.jp 3 H5N1 1 A A A 54 59 1 4 A A 5 1997
More information近畿中国四国農業研究センター研究報告 第7号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
More informationCHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
More informationw NEWS NEWS Y
No.472 FEB. 200315 w NEWS NEWS Y e r Y E t 1 1 y u i B 1 1 Y c fa g f o p mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr mr A 1 !0 1 1
More informationuntitled
---------- - 1 - ----- 1 Q1 5 Q2 5 Q3 5 Q4 6 Q5 6 Q6 7 Q7 7 Q8 7 Q9 8 Q10 : 8 10 Q1 10 Q2 11 Q3 11 12 Q4 12 Q5 HBs HBc _12 Q6 HBe 12 Q7 13 Q8 NAT 15 Q9 15 Q10 15 Q11 HBs 16 Q12 HBV DNA 16 Q13 17-2 - Q14
More information第3章 焼却灰溶融システムの現状、焼却灰溶融スラグのリサイクルの動向・問題点
18 5 23 450 100~150 1300 1998 10 25 1 1 27 1819 60 3 300t 28.8t 2 62 118t16 12.3 16h 24 3 4 120t 9.6t24h 3 4 100t24h 15t24h 3 4 600t24h 500t24h 5 2 300t24h 75t24h 6 8 80 24h 9.6 24h 4 300t24h 52 24 11
More information2 W.T T.S. 70 2 1 238 WBC7400/µl, RBC 386 10 4 /µl, Hb 11.6 g/dl, Ht 36.2%, PLT 25 10 4 /µl AST 19 IU/l, ALT 11 IU/l, LDH 182 IU/l, BUN 15 mg/dl, Cr 0.54 mg/dl, CRP6.83 mg/dl, RF 353.9IU/ml, CCP 28.0IU/ml
More informationMI( MI() 100% 100% 75% 75% 33% 75% 60% 40% 25% 60% 1 2 3 4 5 6 7 8 9 () 12 () () () !! 1. 2. 3. 1. 2. () () () 3-5% ex. ex. 11 ex. () ex. ex. : ex. : (insula) () () ( 2009 ) () ( ) YES! ()
More informationuntitled
E-mail: khatano@fms.saitama-u.ac.jp Tel & Fax: 048-858-3535 Toxin Virus Bacterium Glycolipid Glycoprotein Vero toxin (Stx1 and Stx2) Side view Bottom view H H H H N H Grobotriaosyl Ceramide (Gb 3 : Galα1-4Galβ1-4Glcβ-Cer)
More informationuntitled
16 1109 2005 3 1109 1 16 1109 2 1 5 1 2 3 2 15 1 2 3 3 24 1 2 2 16 1109 1 colere nature 2 1 1982 P, 2 1967 P,135 136 3 16 1109 1 70 2 1 1997 P,68 2 2003 P,203 206 4 16 1109 5 16 1109 1 2 3 4 1 1982 P,17
More information›Áfi¡ŒÎ“F’æ’¶
Shigetaka KATOW 2002 12 13 2 CDC Centers for Disease Control and Prevention CDC TV Dr. Julie L. Gerberding CDC 1 2001 9 11 2001 7 3 2 TV 60 2009 2 1 3 50 30 1976 1 5 BC1157 1 DNA DNA RNA 0100-0006 - -
More informationA5_Catalog-US-JN_ indd
66 22 g 13 g 8 g 5 g 7500 IU 150% 300 mg 600 IU 100 IU 80 mcg 3 mg 3.5 mg 40 mg 4 mg 500 mcg 12 mcg 300 mcg 20 mg 1000 mg 150 mcg 400 mg 15 mg 105 mcg 2 mg 2 mg 180 mcg 125 mcg 15 mg 3.6 g ** 3.8 g **
More information